Irofulven
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-Resistant Prostate Cancer Patients
Conditions
Metastatic Castration-Resistant Prostate Cancer Patients
Trial Timeline
Oct 17, 2018 → Aug 1, 2022
NCT ID
NCT03643107About Irofulven
Irofulven is a phase 2 stage product being developed by Lantern Pharma for Metastatic Castration-Resistant Prostate Cancer Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT03643107. Target conditions include Metastatic Castration-Resistant Prostate Cancer Patients.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-Resistant Prostate Cancer Patients were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03643107 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Castration-Resistant Prostate Cancer Patients